Cooper-Standard Holdings CPS 深 沪
等待开盘 12-16 09:30:00 美东时间
33.21
+0.270
+0.82%
华盛通- 最 高34.4275
- 今 开33.39
- 成交量 16.61万股
- 最 低 32.70
- 昨 收 32.94
- 总市值 5.86亿
- 52周最高 40.67
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 10.375
- 委 比 91.39%
- 总股本 1763.70万
- 历史最高 146.775
- 量 比 1.37
- 振 幅 5.24%
- 历史最低 3.525
- 每 手 1
- 风险率 8.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
今天 09:36
Citigroup Maintains Neutral on Cooper-Standard Holdings, Raises Price Target to $35
Citigroup analyst Michael Ward maintains Cooper-Standard Holdings (NYSE:CPS) with a Neutral and raises the price target from $31 to $35.
今天 05:22
Cooper-Standard Q3 Earnings Call: Balancing Success and Challenges
Cooper-Standard Holdings (($CPS)) has held its Q3 earnings call. Read on for th...
11-04 08:21
电话会总结 ｜ Cooper-Standard(CPS)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Cooper-Standard业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **2025年第三季度：** - 营收：6.955亿美元，同比增长1.5% - 毛利率：12.5%，同比提升140个基点 - 调整后EBITDA：5,330万美元，同比增长超过15.6% - GAAP净亏损：760万美元，较去年同期1,110万美元亏损有所改善 - 调整后净亏损：440万美元（每股0.24美元），较去年同期1,200万美元亏损（每股0.68美元）大幅改善 - 自由现金流：2,700万美元，同比增加超过1,100万美元 - 经营现金流：3,90
11-02 12:01
Cooper-Standard Holdings Lowers FY2025 Sales Guidance from $2.700B-$2.800B to $2.680B-$2.720B vs $2.767B Est
Cooper-Standard Holdings (NYSE:CPS) lowers FY2025 sales outlook from $2.700 billion-$2.800 billion to $2.680 billion-$2.720 billion vs $2.767 billion estimate.
10-31 04:32
Cooper-Standard Holdings Q3 Adj. EPS $(0.24) Misses $0.11 Estimate, Sales $695.502M Miss $698.833M Estimate
Cooper-Standard Holdings (NYSE:CPS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $0.11 by 322.22 percent. This is a 64.71 percent increase over losses of $(0.68) per share
10-31 04:32
Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
The European Commission Has Approved Merck's Keytruda (Pembrolizumab) As Part Of The Treatment Regimen For Resectable Locally Advanced Head And Neck Squamous Cell Carcinoma
KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapyBased on results of KEYNOTE-689, this
10-29 18:48
拓益速递 | 特瑞普利单抗在加拿大正式获批
1. 本材料旨在传递前沿信息，无意向您做任何产品的推广，不作为临床用药指导。 2. 若您想了解具体疾病诊疗信息，请遵从医疗卫生专业人士的意见与指导。 关于特瑞普...
10-29 17:32
Dart Mining NL Issues Options to CPS Capital Group
Dart Mining NL ( ($AU:DTM) ) has shared an announcement. Dart Mining NL announc...
10-29 16:07
